Rani Therapeutics Holdings (RANI) Short term Debt (2020 - 2025)

Rani Therapeutics Holdings' Short term Debt history runs 6 years deep, the most recent figure standing at $13.5 million for Q3 2025.

• On a quarterly basis, Short term Debt fell 8.34% year-over-year to $13.5 million in Q3 2025; TTM through Sep 2025 was $13.5 million, a 8.34% decrease from a year earlier, with the FY2024 full-year figure at $15.0 million, up 206.31% from the prior year.
• Short term Debt eased to $13.5 million in Q3 2025 per RANI's latest filing, from $15.0 million in the prior quarter.
• Across five years, Short term Debt topped out at $15.0 million in Q4 2024 and bottomed at $30000.0 in Q2 2022.
• The 5-year median for Short term Debt is $4.9 million (2023), against an average of $7.0 million.
• Across the five-year window, Short term Debt plunged 99.23% in 2022 and jumped 2121.82% in 2023, its largest moves.
• Year by year, Short term Debt stood at $126000.0 in 2021, then plunged by 56.35% to $55000.0 in 2022, then soared by 8803.64% to $4.9 million in 2023, then soared by 206.31% to $15.0 million in 2024, then slipped by 9.75% to $13.5 million in 2025.
• Per Business Quant, the three latest RANI Short term Debt figures stand at $13.5 million (Q3 2025), $15.0 million (Q2 2025), and $15.0 million (Q1 2025).